Zafgen, Inc. (NASDAQ:ZFGN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.Submission of Matters to a Vote of Security Holders.
Zafgen,Inc. (the Company) held its Annual Meeting of Stockholders
(the Annual Meeting) on June21, 2017. As of April24, 2017, the
record date for the Annual Meeting, there were 27,372,851
outstanding shares of the Companys common stock. The Companys
stockholders voted on the following matters, which are described
in detail in the Companys Definitive Proxy Statement filed with
the U.S. Securities and Exchange Commission (SEC) on April28,
2017: (i)to elect Thomas E. Hughes, Ph.D., John L. LaMattina,
Ph.D. and Frank E. Thomas as Class III directors of the Company
to each serve for a three-year term expiring at the Companys
annual meeting of stockholders in 2020 and until their successors
have been duly elected and qualified (Proposal 1), and (ii)to
ratify the appointment of PricewaterhouseCoopers LLP as the
Companys independent registered public accounting firm for the
fiscal year ending December31, 2017 (Proposal 2).
The Companys stockholders approved the Class III director
nominees recommended for election in Proposal 1 at the Annual
Meeting. The Companys stockholders voted for Class III directors
The Companys stockholders approved Proposal 2. The votes cast at
the Annual Meeting were as follows:
No other matters were submitted to or voted on by the Companys
stockholders at the Annual Meeting.
About Zafgen, Inc. (NASDAQ:ZFGN)
Zafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity. Beloranib is in Phase III stage of development for PWS. It is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor, for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity, as well as other second-generation MetAP2 inhibitors for the treatment of severe obesity. It is also evaluating additional MetAP2 inhibitors beyond Beloranib as a development candidate for the treatment of severe obesity in the general population.